Global Rofecoxib Market Report, History and Forecast 2024-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Rofecoxib Market Report, History and Forecast 2024-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Rofecoxib is a COX-2 selective nonsteroidal anti-inflammatory drug (NSAID). It was marketed by Merck & Co. to treat osteoarthritis, rheumatoid arthritis, juvenile rheumatoid arthritis, acute pain conditions, migraine, and dysmenorrhea.Rofecoxib was available by prescription in both tablet-form and as an oral suspension.
Rofecoxib report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Rofecoxib market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Osteoarthritis and Rheumatoid Arthritis are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Rofecoxib industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Rofecoxib key manufacturers include Merck, Chengdu Meinkai Chemical Co. LTD, Wuhan Xinxin Jiali Biotechnology Co. LTD, Hubei TuoChu Kang Yuan Pharmaceutical Chemical Co. LTD, Pfizer and Tremeau, etc. Merck, Chengdu Meinkai Chemical Co. LTD, Wuhan Xinxin Jiali Biotechnology Co. LTD are top 3 players and held % sales share in total in 2022.
Rofecoxib can be divided into Oral Suspension. and Tablet-Form, etc. Oral Suspension. is the mainstream product in the market, accounting for % sales share globally in 2022.
Rofecoxib is widely used in various fields, such as Osteoarthritis, Rheumatoid Arthritis, Juvenile Rheumatoid Arthritis and Acute Pain Conditions, etc. Osteoarthritis provides greatest supports to the Rofecoxib industry development. In 2022, global % sales of Rofecoxib went into Osteoarthritis filed.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Rofecoxib market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
Merck
Chengdu Meinkai Chemical Co. LTD
Wuhan Xinxin Jiali Biotechnology Co. LTD
Hubei TuoChu Kang Yuan Pharmaceutical Chemical Co. LTD
Pfizer
Tremeau
Segment by Type
Oral Suspension.
Tablet-Form
Osteoarthritis
Rheumatoid Arthritis
Juvenile Rheumatoid Arthritis
Acute Pain Conditions
Migraine
Dysmenorrhea
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Each chapter of the report provides detailed information for readers to understand the Rofecoxib market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Rofecoxib, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Rofecoxib industry.
Chapter 3Historical (2024-2022) and forecast (2024-2034) volume and revenue analysis of Rofecoxib in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Rofecoxib introduction, etc. Rofecoxib Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Rofecoxib market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
Rofecoxib report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Rofecoxib market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Osteoarthritis and Rheumatoid Arthritis are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Rofecoxib industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Rofecoxib key manufacturers include Merck, Chengdu Meinkai Chemical Co. LTD, Wuhan Xinxin Jiali Biotechnology Co. LTD, Hubei TuoChu Kang Yuan Pharmaceutical Chemical Co. LTD, Pfizer and Tremeau, etc. Merck, Chengdu Meinkai Chemical Co. LTD, Wuhan Xinxin Jiali Biotechnology Co. LTD are top 3 players and held % sales share in total in 2022.
Rofecoxib can be divided into Oral Suspension. and Tablet-Form, etc. Oral Suspension. is the mainstream product in the market, accounting for % sales share globally in 2022.
Rofecoxib is widely used in various fields, such as Osteoarthritis, Rheumatoid Arthritis, Juvenile Rheumatoid Arthritis and Acute Pain Conditions, etc. Osteoarthritis provides greatest supports to the Rofecoxib industry development. In 2022, global % sales of Rofecoxib went into Osteoarthritis filed.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Rofecoxib market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
Merck
Chengdu Meinkai Chemical Co. LTD
Wuhan Xinxin Jiali Biotechnology Co. LTD
Hubei TuoChu Kang Yuan Pharmaceutical Chemical Co. LTD
Pfizer
Tremeau
Segment by Type
Oral Suspension.
Tablet-Form
Segment by Application
Osteoarthritis
Rheumatoid Arthritis
Juvenile Rheumatoid Arthritis
Acute Pain Conditions
Migraine
Dysmenorrhea
Segment by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Each chapter of the report provides detailed information for readers to understand the Rofecoxib market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Rofecoxib, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Rofecoxib industry.
Chapter 3Historical (2024-2022) and forecast (2024-2034) volume and revenue analysis of Rofecoxib in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Rofecoxib introduction, etc. Rofecoxib Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Rofecoxib market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices